Quest Diagnostics Inc vs Ishares Msci Spain ETF — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Ishares Msci Spain ETF trades at $59.3. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Ishares Msci Spain ETF pays none, and Ishares Msci Spain ETF is trading nearer its 52-week high, Quest Diagnostics Inc nearer its low. Which is the better fit depends on your goals.
| DGX | EWP | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $60.28 |
52-Week Low | $166.42 | $43.48 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
EWP is trading at $58.94, down 0.86% over the past 24 hours. The technical outlook is bullish, with moving averages signaling strength, while oscillators remain neutral. A dividend of $0.92 is scheduled for payment on June 18, 2026. Recent news highlights European market dynamics, including ECB rate hikes and regional economic performance, which may influence this US-listed stock's sentiment.
The stock's outlook is supported by bullish technical signals, but fundamental data is unavailable, limiting valuation assessment. Key risks include reliance on European economic conditions and potential volatility from monetary policy shifts. Investor sentiment appears mixed, with technical strength offset by a lack of recent fundamental catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →